证券代码：603158 证券简称：腾龙股份 公告编号：2025-069 常州腾龙汽车零部件股份有限公司 关于控股子公司力驰雷奥向其部分股东回购股权暨减资的公告 ■ 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次交易主要系公司控股子公司浙江力驰雷奥环保科技有限公司通过回购股权并减资的方式，回购其 部分股东持有的力驰雷奥合计792万元注册资本，占回购前总注册资本比例为44%，对应的回购资金为 人民币16,940万元。回购并减资完成后，力驰雷奥的注册资本变更为1,008万元，公司持有其96.43%股 权。 常州腾龙汽车零部件股份有限公司（以下简称"公司"、"丙方"）控股子公司浙江力驰雷奥环保科技有限 公司（以下简称"力驰雷奥"、"甲方"）主要从事EGR系统的研发与制造。公司于2025年12月3日召开第 五届董事会第二十四次会议审议通过了《关于控股子公司力驰雷奥向其部分股东回购股权暨减资的议 案》，经过审慎评估，同意力驰雷奥以现金向其部分股东回购股权并减资的方式，回购其部分股东持有 的力驰雷奥合计792万元注 ...

Core Viewpoint - The company plans to reduce the registered capital of its wholly-owned subsidiary, Huaxin Green Source (Inner Mongolia) Environmental Industry Development Co., Ltd., from 250 million to 100 million yuan, which will optimize its asset structure and improve capital utilization [1] Group 1: Capital Reduction Details - The capital reduction does not constitute a related party transaction or a major asset restructuring, and does not require shareholder approval [1] - The company's ownership percentage remains at 100% before and after the capital reduction, which will not affect the consolidated financial statements [1] Group 2: Financial Performance of Huaxin Green Source - For the fiscal year 2024, Huaxin Green Source is projected to achieve revenue of 178 million yuan and a net profit of 20 million yuan [1] - For the first half of 2025, the company expects revenue of 97 million yuan and a net profit of 14 million yuan [1] Group 3: Rationale for Capital Reduction - The capital reduction is a result of the termination of a fundraising project, which is aimed at optimizing the asset structure and enhancing the efficiency of capital utilization [1]

Core Viewpoint - The company plans to change the purpose of repurchased shares from "equity incentive implementation" to "cancellation and capital reduction" as of August 7, 2025, which will reduce the total share capital and registered capital [1] Summary by Sections - **Share Repurchase and Cancellation** - The company will cancel 7.9349 million shares that were repurchased but not used for their original purpose [1] - After the cancellation, the total share capital will decrease from 1.018 billion shares to 1.010 billion shares [1] - **Registered Capital Adjustment** - The registered capital will be reduced from 102 million yuan to 101 million yuan following the share cancellation [1] - **Creditor Rights** - Creditors have 45 days from the announcement date to request repayment or provide guarantees, with specific instructions for claiming debts [1]

Core Points - Jiangzhong Pharmaceutical Co., Ltd. announced a cash dividend of 0.5 yuan per share for the first half of 2025, approved at the temporary shareholders' meeting on September 8, 2025 [1][3]. Distribution Plan - The total cash dividend distribution amounts to 317,498,011 yuan based on a total share capital of 634,996,022 shares [3]. - The distribution is applicable to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the equity registration [2]. Implementation Details - The cash dividends will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited, with shareholders who have designated trading able to receive their dividends on the payment date [4]. - For shareholders who have not designated trading, the dividends will be held by China Securities Depository and Clearing Corporation Limited until they complete the designation [4]. Taxation Information - Individual shareholders holding shares for over one year are exempt from personal income tax on dividends, while those holding for less than one year will have tax deducted upon transfer of shares [7][8]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net dividend of 0.45 yuan per share [9]. Recent Board Decisions - The board approved the acquisition of 70% of Jingcheng Huyao's shares for no more than 70.78393 million yuan to enhance the company's OTC product matrix [13]. - The board also approved the initiation of the second phase of the Smart Decoction Center project with an estimated investment of 11.15 million yuan to expand production capacity [14]. - A decision was made to reduce investment in Sanghai Pharmaceutical by transferring 51.0044% of its shares, with a capital reduction of 39 million yuan [15]. - The board agreed to adjust the disposal plan for the Sangji Project Company, opting for an absorption merger instead of a public transfer [17].

Core Viewpoint - Maanshan Iron & Steel Co., Ltd. (00323) has signed a capital reduction agreement with Baowu Water and eighteen other shareholders, aiming to enhance operational efficiency and effectiveness through a reduction of RMB 538 million [1] Group 1: Capital Reduction Details - The capital reduction involves three shareholders, including Maanshan Iron & Steel, while the other sixteen shareholders will not participate in the reduction [1] - Maanshan Iron & Steel's equity stake in Baowu Water will decrease from 14.977% to 3.151% following the capital reduction [1] Group 2: Operational Impact - The capital reduction is intended to improve Maanshan Iron & Steel's operational efficiency and will not significantly impact its daily operations and financial status [1] - By acquiring the circulating water assets related to its production, Maanshan Iron & Steel aims to lower operational costs and enhance production stability and synergy [1]

Core Viewpoint - Maanshan Iron & Steel Co., Ltd. (00323) has signed a capital reduction agreement with Baowu Water and eighteen other shareholders, reducing its stake in Baowu Water from 14.977% to 3.151% through a capital reduction of RMB 538 million [1] Group 1: Capital Reduction Details - The capital reduction involves three shareholders, including Maanshan Iron & Steel, while the other sixteen shareholders will not participate in the reduction [1] - The capital reduction is aimed at enhancing the operational efficiency and effectiveness of Maanshan Iron & Steel [1] Group 2: Impact on Operations - The capital reduction will not significantly impact the daily operations and financial status of Maanshan Iron & Steel [1] - By retaining water assets closely related to its production, Maanshan Iron & Steel aims to lower operational costs and improve production stability [1]

Core Viewpoint - Tianjin Zhonglv Electric Investment Co., Ltd. has announced a share repurchase plan aimed at canceling shares and reducing registered capital, along with notifying creditors about the implications of this action [1][2]. Group 1: Share Repurchase Plan - The company will use self-raised funds to repurchase shares through centralized bidding, with a total fund amounting to no less than 61.84 million yuan and no more than 92.76 million yuan, at a maximum price of 13.31 yuan per share [2]. - The implementation period for the share repurchase is set for 12 months from the date of approval at the third extraordinary shareholders' meeting in September 2025 [2]. Group 2: Creditor Notification - Following the cancellation of repurchased shares, the company's registered capital will decrease, prompting the company to notify creditors that they have 45 days from the announcement date (September 17, 2025) to claim debts or request guarantees [3]. - Creditors must provide original and photocopied documents proving the existence of the debt relationship, and specific requirements vary for corporate and individual creditors [3].

Group 1 - The company, Shenzhen Baiwei Storage Technology Co., Ltd., has announced a share repurchase plan through centralized bidding, intending to buy back shares worth no less than 20 million yuan and no more than 40 million yuan using its own or raised funds [1] - The repurchase price will not exceed 97.90 yuan per share, and the duration of the buyback will be 12 months from the date of approval by the shareholders' meeting [1] - Some directors, senior executives, and shareholders holding more than 5% of the shares have not completed their reduction plans and will continue to reduce their holdings as originally planned [1]

Core Viewpoint - The company, Tianjin Lianlong New Materials Co., Ltd., has approved a merger between its subsidiaries, Tianjin Aoruifei Biopharmaceutical Co., Ltd. and Tianjin Aolife Biotechnology Co., Ltd., to optimize resource allocation and improve management efficiency [1][9]. Summary by Sections 1. Overview of Related Transactions - The merger will involve Aoruifei absorbing Aolife, leading to Aolife's termination and cancellation of its legal status. Aoruifei will inherit all assets, liabilities, and rights from Aolife, and its registered capital will be reduced from 1.5 billion to 1.282 billion yuan [1][7]. 2. Basic Information of Related Parties - Tianjin Jukanglong Enterprise Management Partnership (Limited Partnership) holds a 30% stake in Aoruifei. The partnership is formed by the company's directors and senior management [2][4]. 3. Basic Information of the Merged Entities - Aolife has a registered capital of 5 million yuan and focuses on biochemistry product R&D and manufacturing. Aoruifei has a registered capital of 10 million yuan and engages in medical research and specialized chemical product sales [4][6]. 4. Arrangements for Merger and Capital Reduction - After the merger, Aoruifei will reduce its registered capital by 218 million yuan, and all assets and liabilities of Aolife will be transferred to Aoruifei [7][8]. 5. Pricing Policy and Basis for the Transaction - The pricing for the merger is based on the profitability and net asset scale of Aoruifei and Aolife, ensuring fairness and reasonableness in the transaction [9][11]. 6. Impact and Purpose of the Merger - The merger aims to optimize resource allocation, enhance management efficiency, and reduce management costs, with no substantial impact on the company's operations or shareholder interests [9][10]. 7. Board and Independent Director Review - The independent directors and the board's audit committee have reviewed and approved the merger, concluding it benefits the company and does not harm shareholder interests [10][11].

Core Viewpoint - Aurora Optoelectronics Co., Ltd. plans to repurchase and cancel a total of 12,065,449 performance compensation shares from specific investors, completing their performance compensation obligations [1][3]. Group 1: Repurchase and Cancellation Details - The company will repurchase shares from several performance compensation obligors at a total price of RMB 1.00, and the repurchased shares will be canceled in batches according to the actual progress [3]. - The repurchased shares represent 0.44% of the company's total share capital before the repurchase [3]. Group 2: Performance Compensation Obligors - Performance compensation obligors Zuo Hongbo and Chu Shuxia are required to compensate a total of 390,706,608 shares, but they currently hold 235,423,715 shares, all of which are subject to judicial freezing [2]. - The company faces significant uncertainty in pursuing compensation from Zuo Hongbo and Chu Shuxia due to their personal asset rights being restricted by other debt disputes [2]. Group 3: Notification to Creditors - The company has notified creditors about the repurchase and cancellation of shares, allowing them 30 days from notification or 45 days from the announcement date to claim debts or request guarantees [3][4]. - Creditors must submit written requests along with relevant proof of debt relationships to the company [4].